BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 24485802)

  • 1. Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-up.
    Agresti R; Crippa F; Sandri M; Martelli G; Tagliabue E; Alessi A; Pellitteri C; Maccauro M; Maugeri I; Barbara P; Rampa M; Moscaroli A; Ferraris C; Carcangiu ML; Bianchi G; Greco M; Bombardieri E
    Breast; 2014 Aug; 23(4):334-40. PubMed ID: 24485802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 99mTc-Tetrofosmin pinhole-SPECT (P-SPECT) and radioguided sentinel node (SN) biopsy and in breast cancer axillary lymph node staging.
    Spanu A; Dettori G; Chessa F; Porcu A; Cottu P; Solinas P; Falchi A; Solinas ME; Scanu AM; Nuvoli S; Madeddu G
    Cancer Biother Radiopharm; 2001 Dec; 16(6):501-13. PubMed ID: 11789027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.
    Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L
    Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.
    Veronesi U; De Cicco C; Galimberti VE; Fernandez JR; Rotmensz N; Viale G; Spano G; Luini A; Intra M; Veronesi P; Berrettini A; Paganelli G
    Ann Oncol; 2007 Mar; 18(3):473-8. PubMed ID: 17164229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET for axillary lymph node staging in primary breast cancer.
    Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer.
    Fujii T; Yajima R; Tatsuki H; Kuwano H
    Anticancer Res; 2016 Apr; 36(4):1785-9. PubMed ID: 27069160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accurate staging with internal mammary chain sentinel node biopsy for breast cancer.
    Gnerlich JL; Barreto-Andrade JC; Czechura T; John JR; Turk MA; Kennedy TJ; Winchester DJ
    Ann Surg Oncol; 2014 Feb; 21(2):368-74. PubMed ID: 24046119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative FDG-PET for axillary metastases in patients with breast cancer.
    Chung A; Liou D; Karlan S; Waxman A; Fujimoto K; Hagiike M; Phillips EH
    Arch Surg; 2006 Aug; 141(8):783-8; discussion 788-9. PubMed ID: 16924086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer.
    Gil-Rendo A; Zornoza G; García-Velloso MJ; Regueira FM; Beorlegui C; Cervera M
    Br J Surg; 2006 Jun; 93(6):707-12. PubMed ID: 16622900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
    Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
    J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonvisualization of axillary sentinel node during lymphoscintigraphy: is there a pathologic significance in breast cancer?
    Brenot-Rossi I; Houvenaeghel G; Jacquemier J; Bardou VJ; Martino M; Hassan-Sebbag N; Pasquier J
    J Nucl Med; 2003 Aug; 44(8):1232-7. PubMed ID: 12902412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
    Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative dynamic lymphoscintigraphy predicts sentinel lymph node metastasis in patients with early breast cancer.
    Nakashima K; Kurebayashi J; Sonoo H; Tanaka K; Ikeda M; Shiiki S; Yamamoto Y; Nomura T; Sohda M; Seki M; Miyake A; Moriya T; Sadahira Y; Mimura H; Fukunaga M
    Breast Cancer; 2010; 17(1):17-21. PubMed ID: 19466508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging.
    Taira N; Ohsumi S; Takabatake D; Hara F; Takashima S; Aogi K; Takashima S; Inoue T; Sugata S; Nishimura R
    Jpn J Clin Oncol; 2009 Jan; 39(1):16-21. PubMed ID: 18997183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
    Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
    J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.
    Aukema TS; Straver ME; Peeters MJ; Russell NS; Gilhuijs KG; Vogel WV; Rutgers EJ; Olmos RA
    Eur J Cancer; 2010 Dec; 46(18):3205-10. PubMed ID: 20719497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
    Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
    J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of the lymphoscintigraphy in the evaluation of non-axillary sentinel lymph node localization in breast cancer.
    Gherghe M; Bordea C; Blidaru A
    Chirurgia (Bucur); 2015; 110(1):26-32. PubMed ID: 25800312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.